The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable

L Chin-Lenn, RH De Boer, E Segelov, GM Marx, TM Hughes, NJ McCarthy, SC White, SS Foo, JJ Rutovitz, S Della-Fiorentina, R Jennens, YC Antill, D Tsoi, MF Cronk, JM Lombard, BE Kiely, JH Chirgwin, A Gorelik, GB Mann